200
Participants
Start Date
December 10, 2012
Primary Completion Date
March 11, 2020
Study Completion Date
March 11, 2020
M6620
Gemcitabine
Cisplatin
Etoposide
Carboplatin
Irinotecan
Long Island Jewish Medical Center - Monter Cancer Center, Lake Success
Virginia Cancer Specialists, PC, Fairfax
Virginia Oncology Associates - Hampton, Norfolk
Greenville Health System, Greenville
Emory University, Atlanta
Vanderbilt University Medical Center, Nashville
OSU - James Comprehensive Cancer Center - Division of Hematology, Columbus
University Hospitals Case Medical Center - Case Comprehensive Cancer Center at, Cleveland
Breslin Cancer Center, Lansing
University Of Minnesota Hospital, Minneapolis
Mayo Clinic - Rochester, Rochester
Northwestern Center for Clinical Research, Chicago
Washington University in St. Louis, St Louis
Texas Oncology, P.A., Dallas
University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics - Partner, Houston
Texas Oncology San Antonio Medical Cente, San Antonio
US Oncology - Texas Oncology-Midtown - Austin Midtown, Austin
Rocky Mountain Cancer Centers, LLP, Denver
Mayo Clinic Arizona, Phoenix
Sharp Memorial Hospital, San Diego
Northwest Cancer Specialists , P.C., Vancouver
Stanford
Freeman Hospital - PARENT, Newcastle upon Tyne
Churchill Hospital - PARENT, Oxford
Beatson West of Scotland Cancer Centre - Dept of Medical Oncology, Glasgow
Royal Marsden Hospital - Dept of Oncology, Sutton
Guy's Hospital - PARENT, London
Sarah Cannon Research Institute UK, London
The Christie - Dept of Oncology, Manchester
Dana Farber Cancer Institute, Boston
Hackensack University Medical Center PARTNER, Hackensack
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY